Type 2 & other diabetes

Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study

BMJPublished Population-based cohort study

An erratum to this article was published (BMJ, 2 Sep 2024 ↗)

Main finding · New onset dementiaResult — go to the resultHazard ratio 0.65 95% CI 0.58–0.73

Authors' conclusion

SGLT-2 inhibitors might prevent dementia, providing greater benefits with longer treatment. As this study was observational and therefore prone to residual confounding and informative censoring, the effect size could have been overestimated. Randomised controlled trials are needed to confirm these findings.

Study context

Population
Adults aged 40–69 years with T2D, Korean National Health Insurance Service data, 2013–21110,885 matched pairs
Exposure
SGLT2i vs DPP-4i initiation
Outcome
New onset dementia
Methodological detailspropensity score matched
  • Propensity score matched

Main finding

As reported in the abstract

mean follow-up 670 (SD 650) days

Hazard ratio

0.65

95% CI 0.58–0.73

By group

SGLT-2 inhibitors

0.22 per 100 person years

DPP-4 inhibitors

0.35 per 100 person years

SGLT-2 inhibitorsvs DPP-4 inhibitors
HR 0.65 (95% CI 0.58–0.73)
People with newly diagnosed dementia
1172

Observational data: associations, not effects.

Secondary outcomes

Control outcomes

HR, genital infections (positive control)
2.67 (2.57 to 2.77)
HR, osteoarthritis related encounters (negative control)
0.97 (0.95 to 0.98)
HR, cataract surgery (negative control)
0.92 (0.89 to 0.96)

Dementia, calibrated for residual confounding measured by cataract surgery

HR for dementia, calibrated
0.70 (0.62 to 0.80)

Dementia by treatment duration

HR of dementia, >2 years of treatment
0.57 (0.46 to 0.70) (95% CI)
HR of dementia, ≤2 years of treatment
0.52 (0.41 to 0.66)
Association greater for >2 years of treatment and persisted across subgroups

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study. BMJ. Published 28 August 2024. doi:10.1136/bmj-2024-079475

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.